Compare Stocks: CLGN, PLUR, KALA, and TPST

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$0.31 -1.7%	$0.33	$0.27 ▼ $3.18	$4.59M	1.67	61,795 shs	30,867 shs
KALA KALA BIO	$0.82 -2.4%	$1.41	$0.59 ▼ $1,030.00	$16.25M	-2.26	71,570 shs	100,555 shs
PLUR Pluri	$1.71 -3.4%	$1.86	$1.45 ▼ $5.68	$19.10M	0.67	18,295 shs	4,606 shs
TPST Tempest Therapeutics	$1.04 +2.0%	$1.04	$0.84 ▼ $12.23	$16.30M	-1.72	296,618 shs	130,341 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	-1.67%	-5.22%	-2.65%	-26.71%	-84.14%
KALA KALA BIO	-2.38%	-13.67%	+11.35%	-66.25%	-99.80%
PLUR Pluri	-3.39%	+7.75%	-7.57%	-27.85%	-65.66%
TPST Tempest Therapeutics	+1.96%	+2.46%	+9.35%	-44.09%	-88.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLGN CollPlant Biotechnologies	$0.31 -1.7%	$0.33	$0.27 ▼ $3.18	$4.59M	1.67	61,795 shs	30,867 shs
KALA KALA BIO	$0.82 -2.4%	$1.41	$0.59 ▼ $1,030.00	$16.25M	-2.26	71,570 shs	100,555 shs
PLUR Pluri	$1.71 -3.4%	$1.86	$1.45 ▼ $5.68	$19.10M	0.67	18,295 shs	4,606 shs
TPST Tempest Therapeutics	$1.04 +2.0%	$1.04	$0.84 ▼ $12.23	$16.30M	-1.72	296,618 shs	130,341 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLGN CollPlant Biotechnologies	-1.67%	-5.22%	-2.65%	-26.71%	-84.14%
KALA KALA BIO	-2.38%	-13.67%	+11.35%	-66.25%	-99.80%
PLUR Pluri	-3.39%	+7.75%	-7.57%	-27.85%	-65.66%
TPST Tempest Therapeutics	+1.96%	+2.46%	+9.35%	-44.09%	-88.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLGN CollPlant Biotechnologies	1.50	Reduce	$12.00	3,740.00% Upside
KALA KALA BIO	2.00	Hold	$1,158.33	141,142.94% Upside
PLUR Pluri	1.00	Sell	N/A	N/A
TPST Tempest Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLGN, PLUR, KALA, and TPST Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/11/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/23/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	TPST Tempest Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	KALA KALA BIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/2/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLGN CollPlant Biotechnologies	$2.37M	1.90	N/A	N/A	$0.48 per share	0.65
KALA KALA BIO	N/A	N/A	N/A	N/A	$0.47 per share	N/A
PLUR Pluri	$1.08M	17.10	N/A	N/A	($0.11) per share	-15.55
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLGN CollPlant Biotechnologies	-$11.49M	-$1.45	N/A	N/A	N/A	-683.68%	-218.81%	-139.28%	N/A
KALA KALA BIO	-$26.98M	-$31.96	N/A	N/A	N/A	N/A	-222.35%	-70.23%	11/10/2026 (Estimated)
PLUR Pluri	-$22.58M	-$4.53	N/A	N/A	N/A	-2,162.08%	N/A	-106.59%	9/23/2026 (Estimated)
TPST Tempest Therapeutics	-$26.26M	-$4.28	N/A	N/A	N/A	N/A	-576.56%	-134.99%	11/4/2026 (Estimated)

Latest CLGN, PLUR, KALA, and TPST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	KALA KALA BIO	-$6.00	-$21.32	-$15.32	-$21.32	$25.00 million	N/A
8/13/2026	Q2 2026	TPST Tempest Therapeutics	-$0.30	-$0.34	-$0.04	-$0.34	N/A	N/A
5/30/2026	Q1 2026	CLGN CollPlant Biotechnologies	-$0.2374	-$0.23	+$0.0074	-$0.23	$0.46 million	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLGN CollPlant Biotechnologies	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLGN CollPlant Biotechnologies	N/A	2.27	1.99
KALA KALA BIO	N/A	6.88	7.91
PLUR Pluri	N/A	0.33	0.33
TPST Tempest Therapeutics	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLGN CollPlant Biotechnologies	21.69%
KALA KALA BIO	24.61%
PLUR Pluri	16.59%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
CLGN CollPlant Biotechnologies	9.60%
KALA KALA BIO	2.24%
PLUR Pluri	43.16%
TPST Tempest Therapeutics	36.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLGN CollPlant Biotechnologies	70	14.44 million	13.05 million	Optionable
KALA KALA BIO	30	19.34 million	18.91 million	Not Optionable
PLUR Pluri	150	10.79 million	6.13 million	No Data
TPST Tempest Therapeutics	20	15.98 million	10.20 million	No Data

CLGN, PLUR, KALA, and TPST Headlines

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

August 13, 2026 | quiverquant.comQ

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | finanznachrichten.de

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

July 21, 2026 | quiverquant.comQ

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | globenewswire.com

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial

July 15, 2026 | quiverquant.comQ

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026 | globenewswire.com

Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | quiverquant.comQ

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | globenewswire.com

Tempest Therapeutics Announces Resignation of Board Director

May 29, 2026 | tipranks.com

Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants

May 29, 2026 | quiverquant.comQ

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026 | globenewswire.com

Tempest Therapeutics Announces Multiple Board Director Resignations

May 22, 2026 | tipranks.com

Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026 | finanznachrichten.de

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026 | globenewswire.com

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026 | globenewswire.com

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 22, 2026 | globenewswire.com

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026 | globenewswire.com

New Strong Buy Stocks for April 10th

April 10, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN, PLUR, KALA, and TPST Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

$0.31 -0.01 (-1.67%)

As of 08/21/2026 03:59 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

KALA BIO NASDAQ:KALA

$0.82 -0.02 (-2.38%)

As of 08/21/2026 03:59 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Pluri NASDAQ:PLUR

$1.71 -0.06 (-3.39%)

As of 08/21/2026 04:00 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Tempest Therapeutics NASDAQ:TPST

$1.04 +0.02 (+1.96%)

As of 08/21/2026 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLGN, PLUR, KALA, and TPST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLGN, PLUR, KALA, and TPST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLGN, PLUR, KALA, and TPST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN, PLUR, KALA, and TPST Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

KALA BIO NASDAQ:KALA

Pluri NASDAQ:PLUR

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLGN, PLUR, KALA, and TPST Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLGN, PLUR, KALA, and TPST Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLGN, PLUR, KALA, and TPST Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN, PLUR, KALA, and TPST Company Descriptions

CollPlant Biotechnologies NASDAQ:CLGN

KALA BIO NASDAQ:KALA

Pluri NASDAQ:PLUR

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools